Philippe Pierre Goupit

Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon.

MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France.

Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets.